wsbdaily | Tue, 20 Dec 2022 03:11:27 EST Where you find Tomorrow’s Hot Stocks Yesterday!
NOT INVESTMENT ADVICE: ALL CONTENT IS PROVIDED 'AS IS' FOR ENTERTAINMENT AND/OR INFORMATIONAL PURPOSES ONLY.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.
WITHOUT WARRANTY OF ANY KIND. YOU BEAR ALL RISKS, INCLUDING ANY RELIANCE ON THE ACCURACY OF ANY INFORMATION.
WE ARE NOT AFFILIATED WITH THE WALLSTREETBETS NOR ANY OTHER COMMUNITY ON REDDIT.
Ocugen, Inc.(OCGN)
Ocugen, Inc.
263 Great Valley Parkway
Suite 160
Malvern, PA 19355
United States
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fu... Read More
Summary & Charts
| Price | $ 1.72 | +0.11 (+6.83%) |
| Day's Range | $ 1.57 - 1.72 | |
| Previous Close | $ 1.61 | |
| Market Cap | $ 372.49M USD | |
| Short Interest % | N/A | |
| Float | N/A | |
| Outstanding | N/A |
| Exchange | NasdaqCM | |
| Industry | Biotechnology | |
| Sector | Healthcare | |
| Volume | 4.56M | |
| Avg. Volume (20 day) | 4.93M | |
| Rel. Volume (20 day) | 0.92 | |
| Rel. Volume (3 month) | 0.92 | |
| Rating | B | Neutral |
| DCF | N/A | Strong Buy |
| Debt/Equity | 14.00 % | Neutral |
| ROE | -56.07 % | Sell |
| ROA | -48.30 % | Sell |
| P/E | -5.91 % | Strong Sell |
| P/B | 3.25 % | Strong Buy |
| Date | Open | High | Low | Close | Change | Volume | R. Vol. (20d) | R. Vol. (3m) | Mentions |
|---|---|---|---|---|---|---|---|---|---|
| Oct 21, 2022 | $ 1.61 | $ 1.72 | $ 1.57 | $ 1.72 | +0.11 | 4,555,116 | 0.92 | 0.92 | 1 |
| Oct 20, 2022 | $ 1.60 | $ 1.70 | $ 1.59 | $ 1.61 | -0.01 | 2,824,295 | 0.57 | 0.57 | |
| Oct 19, 2022 | $ 1.61 | $ 1.65 | $ 1.58 | $ 1.62 | -0.02 | 5,816,087 | 1.14 | 1.16 | |
| Oct 18, 2022 | $ 1.68 | $ 1.71 | $ 1.58 | $ 1.64 | -0.02 | 4,759,641 | 0.94 | 0.95 | |
| Oct 17, 2022 | $ 1.57 | $ 1.69 | $ 1.56 | $ 1.66 | +0.10 | 5,486,912 | 1.10 | 1.09 | |
| Oct 14, 2022 | $ 1.71 | $ 1.74 | $ 1.54 | $ 1.56 | -0.15 | 4,348,366 | 0.88 | 0.85 | |
| Oct 13, 2022 | $ 1.58 | $ 1.71 | $ 1.55 | $ 1.71 | +0.07 | 3,954,597 | 0.75 | 0.77 | |
| Oct 12, 2022 | $ 1.66 | $ 1.67 | $ 1.59 | $ 1.64 | -0.01 | 3,672,195 | 0.69 | 0.71 | |
| Oct 11, 2022 | $ 1.59 | $ 1.75 | $ 1.55 | $ 1.65 | +0.04 | 4,750,010 | 0.88 | 0.92 | |
| Oct 10, 2022 | $ 1.70 | $ 1.70 | $ 1.58 | $ 1.61 | -0.06 | 4,430,176 | 0.81 | 0.85 | |
| Oct 07, 2022 | $ 1.76 | $ 1.77 | $ 1.66 | $ 1.67 | -0.13 | 5,341,113 | 0.98 | 1.01 | |
| Oct 06, 2022 | $ 1.83 | $ 1.85 | $ 1.76 | $ 1.80 | -0.04 | 4,466,678 | 0.83 | 0.84 | |
| Oct 05, 2022 | $ 1.81 | $ 1.86 | $ 1.76 | $ 1.84 | -0.03 | 4,359,623 | 0.82 | 0.82 | |
| Oct 04, 2022 | $ 1.84 | $ 1.88 | $ 1.81 | $ 1.87 | +0.09 | 4,919,774 | 0.91 | 0.92 | |
| Oct 03, 2022 | $ 1.80 | $ 1.83 | $ 1.72 | $ 1.78 | 4,211,393 | 0.78 | 0.79 | ||
| Sep 30, 2022 | $ 1.77 | $ 1.86 | $ 1.76 | $ 1.78 | -0.02 | 3,517,053 | 0.65 | 0.66 | |
| Sep 29, 2022 | $ 1.94 | $ 1.98 | $ 1.78 | $ 1.80 | -0.23 | 5,646,194 | 1.04 | 1.05 | |
| Sep 28, 2022 | $ 2.07 | $ 2.09 | $ 1.85 | $ 2.03 | +0.21 | 12,398,074 | 2.33 | 2.31 | |
| Sep 27, 2022 | $ 1.81 | $ 1.86 | $ 1.77 | $ 1.82 | +0.07 | 5,242,081 | 1.07 | 0.99 | |
| Sep 26, 2022 | $ 1.82 | $ 1.90 | $ 1.75 | $ 1.75 | -0.04 | 3,835,784 | 0.79 | 0.73 |
News
The latest news about Ocugen, Inc. (OCGN).
GlobeNewsWire | 2022-10-06 08:00:00
MALVERN, Pa., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company will present at two important conferences this month.
GlobeNewsWire | 2022-09-29 07:30:00
MALVERN, Pa., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen, will participate in an in-person fireside chat at the Chardan 6 th Annual Genetic Medicines Conference being held October 3-4, 2022 in New York, NY.
InvestorPlace | 2022-09-28 10:15:22
Ocugen (NASDAQ: OCGN ) stock was up nearly 15% today in premarket trading after the biotechnology company announced that Washington University has signed a licensing agreement with the company for its intranasal Covid-19 vaccine. However, after the market opened, it dropped down to only about 3% in the green.
The Motley Fool | 2022-09-01 18:28:16
The company appointed not one, but two new top managers to crucial posts.
The Motley Fool | 2022-08-24 15:36:28
An analyst thinks the biotech could have an important new gene therapy on its hands.
MarketBeat | 2022-08-24 01:12:09
This article discusses the current state of Ocugen and Amarin, two penny stocks that highlight the risk and (potential) reward of penny stock investing.
The Motley Fool | 2022-08-13 09:45:00
A moonshot won't be necessary, but it'll require a bit of a pivot.
Earnings
| Date | Time | EPS Expected | EPS Reported | % | Revenue Expected | Revenue Reported | % |
|---|---|---|---|---|---|---|---|
| 2022-11-07 | BMO | -0.1 | -- | -- | -- | -- | -- |
| 2022-08-05 | BMO | -0.08 | -0.09 | 12.5% | -- | -- | -- |
| 2022-05-06 | BMO | -- | -- | -- | -- | -- | -- |
| 2022-02-25 | BMO | -0.06 | -0.07 | 16.66% | 14M | -- | -- |
| 2021-11-09 | BMO | -0.04 | -0.05 | 25% | -- | -- | -- |
| 2021-08-06 | BMO | -0.03 | -0.13 | 333.33% | -- | -- | -- |
| 2021-05-07 | BMO | 0.5 | -0.04 | -108% | 78M | -- | -- |
| 2020-11-06 | BMO | -0.02 | -0.07 | 250% | -- | -- | -- |
Top Discussions
These are the top discussions over the last 24-hours that mention the OCGN stock ticker symbol.
Unusual Option Activity
Option contracts that are trading at a significantly higher volume relative to the contract's open interest. These might provide some insight into what "smart money" is doing with large volume orders.
| Type | Strike | Exp Date | DTE | Bid | Ask | Last | Volume | Open Interest | Vol/OI | IV |
|---|---|---|---|---|---|---|---|---|---|---|
| CALL | $ 2.50 | 11/24/22 | 33 | $ 0.00 | $ 0.10 | $ 0.03 | 80 | 31 | 2.58 | 1.11% |
| CALL | $ 1.50 | 12/01/22 | 40 | $ 0.12 | $ 1.57 | $ 0.15 | 45 | 11 | 4.09 | 4.88% |
| CALL | $ 22.50 | 01/18/24 | 453 | $ 16.95 | $ 19.50 | $ 17.69 | 300 | 120 | 2.50 | 0.00% |
Last Updated: Fri, 21 Oct 2022 23:15 EST
Failures to Deliver
Each point represents the aggregate net balance of shares that failed to be delivered as of a particular settlement date.
Please note that fails-to-deliver can occur for a number of reasons on both long and short sales. Therefore, fails-to-deliver are not necessarily the result of short selling, nor evidence of abusive “naked” short selling. For more information on short selling and fails-to-deliver, see Key Points About Regulation SHO, Division of Market Regulation, and Final Rule: Short Sales.
Last Updated: Tue, 14 Dec 2021 12:00 EST
@wsbdaily
wsbdaily